News | August 15, 2024
HCAH Kolkata Center achieves NABH Certification
Becomes the first rehab & recovery center in east India to earn NABH accreditation
Becomes the first rehab & recovery center in east India to earn NABH accreditation
The clinical trial will be conducted at 19 sites with 10,335 participants across India
These results add to the growing body of evidence indicating a single dose of ABRYSVO provides strong immune protection against outcomes caused by RSV
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Pradaxa Capsules, 110 mg of Boehringer Ingelheim Pharmaceuticals
European markets now contribute 51% of our business revenue up from 43% in Q4 FY24 and 34% in Q1 FY24
Third approval in China for AstraZeneca and Daiichi Sankyo’s Enhertu in less than two years
CN201 is a next generation CD3xCD19 bispecific antibody that augments and diversifies Merck’s pipeline, with potential applications in B-cell malignancies and autoimmune diseases
The inspection was concluded with zero observations
Valbenazine Capsules had annual sales of US $1,993.6 mn in the United States (IQVIA MAT June 2024)
Research & Development (R&D) investments for the quarter stood at Rs. 392.5 crore which is 6.3% of its revenues
Subscribe To Our Newsletter & Stay Updated
